3 recruiting, 2 not yet recruiting, 2 terminated, 1 active not recruiting. 2 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow TP53 Gene Mutation: new trials by email Literature Review of TP53 Gene Mutation trials Research Report on TP53 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma Firsekibart + Tislelizumab + Lenvatinib - HCC - Hepatocellular Carcinoma, TP53 Gene Mutation | Not applicable | Not yet recruiting | Tongji Hospital | 25 | 2026-05-01 | 2026-04-17 |
| Germline Genetic Testing of the TP53 Gene TP53 Gene Mutation, Multi-Gene Transcriptional Profiling | Recruiting | European Institute of Oncology | 1940 | 2026-01-29 | 2026-02-19 | |
| Oral-ATO for TP53-mutated Myeloid Malignancies Oral arsenic trioxide - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Recruiting | The University of Hong Kong | 30 | 2025-02-07 | 2025-06-10 |
| Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma Endometrial Neoplasms, TP53 Gene Mutation | Unknown | Peking Union Medical College Hospital | 110 | 2024-09-01 | 2024-07-26 | |
| Patogenic Mutation in 5 Genes co-occuring mutation - Colorectal Cancer, APC Gene Mutation | Completed | Dr Cipto Mangunkusumo General Hospital | 22 | 2021-05-01 | 2021-07-26 | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress Data and Specimen Collection - Li-Fraumeni Syndrome, TP53 Gene Mutation | Recruiting | Dana-Farber Cancer Institute | 1500 | 2020-09-15 | 2026-03-27 | |
| The p53 Colorectal Cancer Trial Cyclophosphamide - Colorectal Cancer Metastatic, Colorectal Cancer Stage IV | Phase 2 | Terminated | Haukeland University Hospital | 12 | 2017-05-09 | 2021-01-22 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab - Adult Solid Neoplasm, Bladder Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 11 | 2015-12-28 | 2026-10-19 |
Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Chromosomal Instability (1) · Chromosome 17 deletion (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Myelomonocytic, Chronic (1) · Li-Fraumeni Syndrome (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Neoplasms (9) · Neoplasms by Site (6) · Neoplasms by Histologic Type (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Leukemia (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Arsenic Trioxide (1) · Cyclophosphamide (1) · Decitabine (1) · MVAp53 vaccine (1) · Specimen Handling (1) · axatilimab (1) · lenvatinib (1) · pembrolizumab (1) · tislelizumab (1) · venetoclax (1)
City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Dr Cipto Mangunkusumo General Hospital (1) · European Institute of Oncology (1) · Haukeland University Hospital (1) · Northside Hospital, Inc. (1) · Peking Union Medical College Hospital (1) · Rutgers, The State University of New Jersey (1) · The University of Hong Kong (1) · Tongji Hospital (1)
United States (4) · Hong Kong (1) · Indonesia (1) · Italy (1) · Norway (1)
Harinder Gill, MD (1) · Judy E Garber, MD, MPH (1) · Roger Strair (1) · Vincent Chung (1)
PMID 20602996, PMID 20876310, PMID 21654748, PMID 23733335, PMID 24639350, PMID 25047706, PMID 25157821, PMID 25484881, PMID 26358057, PMID 28126925, PMID 28212753, PMID 29632729, PMID 30425048, PMID 31940491, PMID 32002295, PMID 32499238, PMID 32605996, PMID 32730593, PMID 33057635, PMID 33415170, PMID 34249942, PMID 34255353, PMID 34298810, PMID 34771453, PMID 35030341, PMID 35352025, PMID 35965420, PMID 36226545, PMID 36459673, PMID 36549780, PMID 37370821, PMID 39133921, PMID 39292927, PMID 39457618, PMID 7506935
P30CA072720 (1), R01CA242218 (1)